Glucocorticoid-induced osteoporosis: an update

被引：254

作者：

Mazziotti, Gherardo

Angeli, Alberto

Bilezikian, John P.

Canalis, Ernesto

Giustina, Andrea ^{[1
]}

机构：

[1] Univ Brescia, Spedali Civili, Dept Internal Med, I-25125 Brescia, Italy

[2] Univ Turin, Azienda Osped San Luigi Gonzaga, Dept Internal Med, I-10043 Turin, Italy

[3] Columbia Univ, Coll Phys & Surg, Dept Med, New York, NY 10032 USA

[4] St Francis Hosp & Med Ctr, Dept Res, Hartford, CT 06010 USA

来源：

TRENDS IN ENDOCRINOLOGY AND METABOLISM | 2006年 / 17卷 / 04期

关键词：

D O I：

10.1016/j.tem.2006.03.009

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Glucocorticoid-induced osteoporosis occurs in two phases: a rapid, early phase in which bone mineral density is reduced, possibly as a result of excessive bone resorption, and a slower, progressive phase in which bone mineral density declines because of impaired bone formation. Although the indirect effects of glucocorticoids on bone are evident, their direct effects on osteoblasts, osteoclasts and osteocytes are primarily operative in the pathogenesis of glucocorticoid-induced osteoporosis. The management of patients exposed to glucocorticoids includes general health measures, sufficient calcium and vitamin D, and reducing the therapeutic regimen to the minimal effective dose. The gold standard in the pharmacological treatment of glucocorticoid-induced osteoporosis in postmenopausal women involves the use of bisphosphonates, which should be started soon after beginning chronic glucocorticoid therapy. Anabolic and alternative therapeutic strategies are currently under investigation in glucocorticoid-induced osteoporosis.

引用

页码：144 / 149

页数：6

共 69 条

[1] CD40 ligand blocks apoptosis induced by tumor necrosis factor α, glucocorticoids, and etoposide in osteoblasts and the osteocyte-like cell line murine long bone osteocyte-Y4 [J].